Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Is Insmed (INSM) Undervalued Following Japan Approval For BRINSUPRI?

31 August 2026 · By · Wire by Fusion42

Published

31 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Japan

◆ Source

Read at simplywall.st →

◆ Verified

Fusion42 · 1 September 2026 · Fusion42 review

Insmed has received Japan approval for BRINSUPRI tablets in non-cystic fibrosis bronchiectasis, adding to existing US and EU approvals and expanding its global market. The approval reinforces growth expectations, with the stock considered undervalued relative to analyst fair value estimates near $197 per share.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must act now to reprice your biotech portfolio as Insmed's global approval for BRINSUPRI opens Japan, creating fresh demand and requiring an update to your market models.

◆ Coverage

1 source · 31 Aug 2026

◆ Related on Wire

◆ Topics

Biotechdrug-approvaljapanbiotechrare-diseasemarket-expansion